A Phase 3 interventional study of Telmisartan 80mg and Rosuvastatin 20mg in Hypertension and Hyperlipidemia, sponsored by IlDong Pharmaceutical Co Ltd. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-03-14.
Sponsored by IlDong Pharmaceutical Co Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.
Among the 99 studies testing telmisartan in Hypertension, this one is the 43rd largest by planned enrollment, is one of 2 that started in 2013, is one of 40 in phase 3, and was the 53rd registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5 · Phase 3 40 · Phase 4 32
First in 1997; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 310 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 184 across the 99 interventional studies. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 99 have an industry lead sponsor. The 10 most frequent:
IlDong Pharmaceutical Co Ltd is the lead sponsor of 50 studies on the registry; 1 is open to participants now.
IlDong Pharmaceutical Co Ltd has 9 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 99 studies testing telmisartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To identify efficacy and safety of Telmisartan/Rosuvastatin co-administration in hyperlipidemia control in hypertensive patients with hyperlipidemia compared to each monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PO, Once Daily, 8 weeks
Drug: Telmisartan 80mg · Drug: Rosuvastatin 20mg · Drug: Placebo(for Rosuvastatin 10mg)
PO, Once Daily, 8weeks
Drug: Telmisartan 80mg · Drug: Rosuvastatin 10mg · Drug: Placebo(for Rosuvastatin 20mg)
PO, Once Daily, 8 weeks
Drug: Rosuvastatin 20mg · Drug: Placebo(for Telmisartan 80mg) · Drug: Placebo(for Rosuvastatin 10mg)
PO, Once Daily, 8 weeks
Drug: Rosuvastatin 10mg · Drug: Placebo(for Telmisartan 80mg) · Drug: Placebo(for Rosuvastatin 20mg)
PO, Once Daily, 8 weeks
Drug: Telmisartan 80mg · Drug: Placebo(for Telmisartan 80mg) · Drug: Placebo(for Rosuvastatin 20mg)
PO, Once Daily, 8 weeks
Drug: Placebo(for Telmisartan 80mg) · Drug: Placebo(for Rosuvastatin 20mg) · Drug: Placebo(for Rosuvastatin 10mg)
•Change in seated diastolicblood pressure at 8 weeks compared to the base value
Time frame: at the 8 weeks
Change in LDL-Cat 8 weeks compared to the base value (% change)
Time frame: at the 8 weeks
Change in seateddiastolic blood pressure
Time frame: at 2,4 8 weeks
Change in seated systolic blood pressure
Time frame: at 2,4,8weeks
Rate of patients achieving a therapeutic purpose according to JNC VII Guideline [therapeutic purpose for blood pressure: < 140/90 mmHg (however, < 130/80 mmHg for Group III)]
Time frame: at 2, 4 and 8 weeks
Change in LDL-Cat compared to the base value (% change)
Time frame: 2, 4 and 8 weeks
Change in TC, TG, HDL-C and Apolipoprotein B compared to the base value (% change)
Time frame: at 2, 4 and 8 weeks
Rate of patients achieving a therapeutic purpose according to NCEP ATP III Guideline therapeutic purpose for LDL-C- (Group I: < 160 mg/dL, Group II: < 130 mg/dL, Group III: < 100 mg/dL)
Time frame: at 2, 4 and 8 weeks
The record gives a start of May 2013 and a primary completion of Dec 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telmisartan · Rosuvastatin
IlDong Pharmaceutical Co Ltd →